Vetmedin for Dogs |  Vetmedin is a pet medication which can open up the main blood vessels to the heart to reduce the pressure. It can also make the heart work more efficiently and clinical studies indicate that this can increase life expectancy. This medication is commonly used to treat heart failure in dogs. Dogs may need to take this medication for the rest of their lives though improvements can usually be seen in a few days. The medication is available in different strengths for different sized animals and is in the form of chewable tablets so it is easy to administer.
| | | | | | Vetmedin is used mostly in dogs with defective heart valves. (Valvular insufficiency or regurgitation, often as a result of nodular endocardiosis.) If the
valves in the heart fail to operate properly, blood flows back when the
valves is supposed to be closed, making the heart less efficient as a
pump. This also makes a whooshing sound in the heart, called a heart
murmur, which vets can hear using a stethoscope. Vetmedin acts on the
muscle of the heart and of blood vessel walls, helping the heart to beat
more efficiently.
Vetmedin is also used to treat heart problems where the muscle has become stretched and weak (dilated cardiomyopathy). The heart muscle can contract more powerfully, improving circulation to the body tissues. Vetmedin can be used on its own, but usually one or more
other drugs are used to add edto increase the beneficial effects.
Vetmedin is not suitable for dogs under the age of six months and should not be given to pregnant or nursing dogs. Care should also be taken with animals suffering from conditions such as diabetes and who are already taking other medications. Your vet will be able to determine if there is a risk of interactions with any other pet medication. Vetmedin can only be obtained with a prescription from the vet. Buying prescription pet meds online still requires a written prescription, which must be sent with the order before the drugs can be supplied. | Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
Vetmedin Flavour Tablets, containing 1.25 mg or 5.0 mg pimobendan per tablet.
Uses
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.
Dosage and administration
See dosing table below.
Vetmedin 1.25 mg and 5.0 mg Tablets Dosage Guide
| Bodyweight
| Daily Dosage
| Morning
| Evening
| (kg)
| (mg)
| 1.25 mg
| 5.0 mg
| 1.25 mg
| 5.0 mg
| < 5
| 1.25
| ½
| -
| ½
| -
| 5-10
| 2.5
| 1
| -
| 1
| -
| 11-20
| 5
| -
| ½
| -
| ½
| 21-40
| 10
| -
| 1
| -
| 1
| 41-60
| 20
| -
| 2
| -
| 2
| > 60
| 30
| -
| 3
| -
| 3
|
Vetmedin Flavour Tablets should be administered orally at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg bodyweight. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later. Each dose should be given approximately one hour before feeding. The tablet is flavoured and may be given as a treat. The large size of 5.0 mg can be readily divided into two halves, using the scored line on the tablet to give a dose that contains 2.5 mg. Do not exceed the recommended dosage.
Determine the bodyweight accurately before prescribing to ensure administration of the correct dosage.
Vetmedin Flavour Tablets may be combined with a diuretic treatment such as furosemide.
This product should be used only in dogs with cardiac insufficiency. Contra-indications, warnings, etc
Vetmedin Tablets should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.
In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating bitches if the expected therapeutic benefits overweigh the potential risk.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. Do not exceed the recommended dosage.
In the case of overdose, symptomatic treatment should be initiated.
Dispose of used packaging in the household refuse. Unused product should be returned to the Veterinary Surgeon.
For animal treatment only.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Pharmaceutical precautions
Do not store above 25°C.
Store in the original package tightly closed in order to protect from moisture.
Keep out of reach and sight of children.
Legal category
POM-V
Packaging Quantities
50 tablets or 100 tablets of 1.25 mg tablets packed in white child-resistant polypropylene bottles.
50 tablets of 5.0 mg tablets packed in white child-resistant polypropylene bottles.
Further information
Pharmacodynamic properties
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity.
Pharmacokinetic particulars
Absorption:
Following oral administration of pimobendan, the absolute biovailability of the active principle is 60 - 63 %. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution:
The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93 %.
Metabolism:
The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.
Elimination:
The plasma elimination half-life of pimobendan is 0.4 + 0.1 hours, consistent with the high clearance of 90 + 19 ml/min/kg and a short mean residence time of 0.5 + 0.1 hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 + 0.3 hours. Almost the entire dose is eliminated via faeces.
Marketing authorisation number
Vm 00015/4077 Vetmedin 1.25 mg Flavour Tablets.
Vm 00015/4076 Vetmedin 5.0 mg Flavour Tablets.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
Vetmedin Flavour Tablets, containing 1.25 mg or 5.0 mg pimobendan per tablet.
Uses
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.
Dosage and administration
See dosing table below.
Vetmedin 1.25 mg and 5.0 mg Tablets Dosage Guide
| Bodyweight
| Daily Dosage
| Morning
| Evening
| (kg)
| (mg)
| 1.25 mg
| 5.0 mg
| 1.25 mg
| 5.0 mg
| < 5
| 1.25
| ½
| -
| ½
| -
| 5-10
| 2.5
| 1
| -
| 1
| -
| 11-20
| 5
| -
| ½
| -
| ½
| 21-40
| 10
| -
| 1
| -
| 1
| 41-60
| 20
| -
| 2
| -
| 2
| > 60
| 30
| -
| 3
| -
| 3
|
Vetmedin Flavour Tablets should be administered orally at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg bodyweight. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later. Each dose should be given approximately one hour before feeding. The tablet is flavoured and may be given as a treat. The large size of 5.0 mg can be readily divided into two halves, using the scored line on the tablet to give a dose that contains 2.5 mg. Do not exceed the recommended dosage.
Determine the bodyweight accurately before prescribing to ensure administration of the correct dosage.
Vetmedin Flavour Tablets may be combined with a diuretic treatment such as furosemide.
This product should be used only in dogs with cardiac insufficiency. Contra-indications, warnings, etc
Vetmedin Tablets should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.
In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating bitches if the expected therapeutic benefits overweigh the potential risk.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. Do not exceed the recommended dosage.
In the case of overdose, symptomatic treatment should be initiated.
Dispose of used packaging in the household refuse. Unused product should be returned to the Veterinary Surgeon.
For animal treatment only.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Pharmaceutical precautions
Do not store above 25°C.
Store in the original package tightly closed in order to protect from moisture.
Keep out of reach and sight of children.
Legal category
POM-V
Packaging Quantities
50 tablets or 100 tablets of 1.25 mg tablets packed in white child-resistant polypropylene bottles.
50 tablets of 5.0 mg tablets packed in white child-resistant polypropylene bottles.
Further information
Pharmacodynamic properties
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity.
Pharmacokinetic particulars
Absorption:
Following oral administration of pimobendan, the absolute biovailability of the active principle is 60 - 63 %. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution:
The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93 %.
Metabolism:
The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.
Elimination:
The plasma elimination half-life of pimobendan is 0.4 + 0.1 hours, consistent with the high clearance of 90 + 19 ml/min/kg and a short mean residence time of 0.5 + 0.1 hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 + 0.3 hours. Almost the entire dose is eliminated via faeces.
Marketing authorisation number
Vm 00015/4077 Vetmedin 1.25 mg Flavour Tablets.
Vm 00015/4076 Vetmedin 5.0 mg Flavour Tablets.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
Vetmedin Flavour Tablets, containing 1.25 mg or 5.0 mg pimobendan per tablet.
Uses
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.
Dosage and administration
See dosing table below.
Vetmedin 1.25 mg and 5.0 mg Tablets Dosage Guide
| Bodyweight
| Daily Dosage
| Morning
| Evening
| (kg)
| (mg)
| 1.25 mg
| 5.0 mg
| 1.25 mg
| 5.0 mg
| < 5
| 1.25
| ½
| -
| ½
| -
| 5-10
| 2.5
| 1
| -
| 1
| -
| 11-20
| 5
| -
| ½
| -
| ½
| 21-40
| 10
| -
| 1
| -
| 1
| 41-60
| 20
| -
| 2
| -
| 2
| > 60
| 30
| -
| 3
| -
| 3
|
Vetmedin Flavour Tablets should be administered orally at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg bodyweight. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later. Each dose should be given approximately one hour before feeding. The tablet is flavoured and may be given as a treat. The large size of 5.0 mg can be readily divided into two halves, using the scored line on the tablet to give a dose that contains 2.5 mg. Do not exceed the recommended dosage.
Determine the bodyweight accurately before prescribing to ensure administration of the correct dosage.
Vetmedin Flavour Tablets may be combined with a diuretic treatment such as furosemide.
This product should be used only in dogs with cardiac insufficiency. Contra-indications, warnings, etc
Vetmedin Tablets should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.
In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating bitches if the expected therapeutic benefits overweigh the potential risk.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. Do not exceed the recommended dosage.
In the case of overdose, symptomatic treatment should be initiated.
Dispose of used packaging in the household refuse. Unused product should be returned to the Veterinary Surgeon.
For animal treatment only.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Pharmaceutical precautions
Do not store above 25°C.
Store in the original package tightly closed in order to protect from moisture.
Keep out of reach and sight of children.
Legal category
POM-V
Packaging Quantities
50 tablets or 100 tablets of 1.25 mg tablets packed in white child-resistant polypropylene bottles.
50 tablets of 5.0 mg tablets packed in white child-resistant polypropylene bottles.
Further information
Pharmacodynamic properties
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity.
Pharmacokinetic particulars
Absorption:
Following oral administration of pimobendan, the absolute biovailability of the active principle is 60 - 63 %. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution:
The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93 %.
Metabolism:
The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.
Elimination:
The plasma elimination half-life of pimobendan is 0.4 + 0.1 hours, consistent with the high clearance of 90 + 19 ml/min/kg and a short mean residence time of 0.5 + 0.1 hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 + 0.3 hours. Almost the entire dose is eliminated via faeces.
Marketing authorisation number
Vm 00015/4077 Vetmedin 1.25 mg Flavour Tablets.
Vm 00015/4076 Vetmedin 5.0 mg Flavour Tablets.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
Hard gelatin capsules orange to brown in colour, containing 5 mg pimobendan per capsule.
Excipients: Titanium Dioxide (E171) 1.2320 mg/capsule and Sunset Yellow (E110) 0.3080 mg/capsule.
Uses
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.
Dosage and administration
See dosing table below.
Vetmedin 5 mg Capsules Dosage Guide
| Bodyweight (kg)
| Daily Dosage (mg)
| Morning
| Evening
| 21-40
| 10
| 1
| 1
| 41-60
| 20
| 2
| 2
| >60
| 30
| 3
| 3
|
Vetmedin capsules should be administered orally (approximately one hour before feeding) at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later.
Determine the bodyweight accurately before prescribing to ensure administration of the correct dosage.
In cases of mild congestive heart failure, a daily dosage at the lower end of the dose range may be adequate. If, however, a clear response is not observable within one week, the dosage should be raised.
Vetmedin capsules may be combined with a diuretic treatment such as frusemide. Contra-indications, warnings, etc
Vetmedin capsules should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
Do not exceed the recommend dosage.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.
In studies with rats and rabbits, pimobendan had no effect on fertility and embryotoxic effects occurred only at maternotoxic doses. In experiments with rats it has been shown that pimobendan is excreted into milk. No information is available on the safety of Vetmedin in pregnant and lactating bitches.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected.
In the case of overdose, symptomatic treatment should be initiated.
User precautions
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only.
Pharmaceutical precautions
Do not store above 25°C.
Store in a dry place.
Store in tightly closed original container.
Keep out of the reach and sight of children.
Legal category
POM-V
Packaging Quantities
100 capsules of 5 mg capsules packed in white child-resistant polypropylene bottles.
Further information
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pharmacodynamic properties
Pimobendan exerts its stimulatory myocardial effect by a dual mode of action: it increases calcium sensitivity of cardiac myofilaments and inhibits phosphodiesterase (type III). It also exhibits a vasodilatory action through inhibition of phosphodiesterase III activity
Pharmacokinetic particulars
Absorption
Following oral administration of Vetmedin capsules the absolute bioavailability of the active principle is 60 – 63%. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution The volume of distribution is 2.61/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93%
Metabolism
The compound is oxidatively demethylated to its major active metabolite (UD-CG12). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulphates.
Elimination The plasma elimination half-life of pimobendan is 0.4±0.1 hours which is consistent with a high clearance of 90±19 ml/min/kg and a short mean residence time of 0.5 ± 0.1hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 ± 0.3 hours. Almost the entire dose is eliminated via faeces.
Marketing authorisation number
Vm 00015/4050 Vetmedin 5 mg Capsules.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
Hard gelatin capsules orange to brown in colour, containing 5 mg pimobendan per capsule.
Excipients: Titanium Dioxide (E171) 1.2320 mg/capsule and Sunset Yellow (E110) 0.3080 mg/capsule.
Uses
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.
Dosage and administration
See dosing table below.
Vetmedin 5 mg Capsules Dosage Guide
| Bodyweight (kg)
| Daily Dosage (mg)
| Morning
| Evening
| 21-40
| 10
| 1
| 1
| 41-60
| 20
| 2
| 2
| >60
| 30
| 3
| 3
|
Vetmedin capsules should be administered orally (approximately one hour before feeding) at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later.
Determine the bodyweight accurately before prescribing to ensure administration of the correct dosage.
In cases of mild congestive heart failure, a daily dosage at the lower end of the dose range may be adequate. If, however, a clear response is not observable within one week, the dosage should be raised.
Vetmedin capsules may be combined with a diuretic treatment such as frusemide. Contra-indications, warnings, etc
Vetmedin capsules should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
Do not exceed the recommend dosage.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.
In studies with rats and rabbits, pimobendan had no effect on fertility and embryotoxic effects occurred only at maternotoxic doses. In experiments with rats it has been shown that pimobendan is excreted into milk. No information is available on the safety of Vetmedin in pregnant and lactating bitches.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected.
In the case of overdose, symptomatic treatment should be initiated.
User precautions
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only.
Pharmaceutical precautions
Do not store above 25°C.
Store in a dry place.
Store in tightly closed original container.
Keep out of the reach and sight of children.
Legal category
POM-V
Packaging Quantities
100 capsules of 5 mg capsules packed in white child-resistant polypropylene bottles.
Further information
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pharmacodynamic properties
Pimobendan exerts its stimulatory myocardial effect by a dual mode of action: it increases calcium sensitivity of cardiac myofilaments and inhibits phosphodiesterase (type III). It also exhibits a vasodilatory action through inhibition of phosphodiesterase III activity
Pharmacokinetic particulars
Absorption
Following oral administration of Vetmedin capsules the absolute bioavailability of the active principle is 60 – 63%. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution The volume of distribution is 2.61/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93%
Metabolism
The compound is oxidatively demethylated to its major active metabolite (UD-CG12). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulphates.
Elimination The plasma elimination half-life of pimobendan is 0.4±0.1 hours which is consistent with a high clearance of 90±19 ml/min/kg and a short mean residence time of 0.5 ± 0.1hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 ± 0.3 hours. Almost the entire dose is eliminated via faeces.
Marketing authorisation number
Vm 00015/4050 Vetmedin 5 mg Capsules.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
Vetmedin Flavour Tablets, containing 1.25 mg or 5.0 mg pimobendan per tablet.
Uses
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.
Dosage and administration
See dosing table below.
Vetmedin 1.25 mg and 5.0 mg Tablets Dosage Guide
| Bodyweight
| Daily Dosage
| Morning
| Evening
| (kg)
| (mg)
| 1.25 mg
| 5.0 mg
| 1.25 mg
| 5.0 mg
| < 5
| 1.25
| ½
| -
| ½
| -
| 5-10
| 2.5
| 1
| -
| 1
| -
| 11-20
| 5
| -
| ½
| -
| ½
| 21-40
| 10
| -
| 1
| -
| 1
| 41-60
| 20
| -
| 2
| -
| 2
| > 60
| 30
| -
| 3
| -
| 3
|
Vetmedin Flavour Tablets should be administered orally at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg bodyweight. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later. Each dose should be given approximately one hour before feeding. The tablet is flavoured and may be given as a treat. The large size of 5.0 mg can be readily divided into two halves, using the scored line on the tablet to give a dose that contains 2.5 mg. Do not exceed the recommended dosage.
Determine the bodyweight accurately before prescribing to ensure administration of the correct dosage.
Vetmedin Flavour Tablets may be combined with a diuretic treatment such as furosemide.
This product should be used only in dogs with cardiac insufficiency. Contra-indications, warnings, etc
Vetmedin Tablets should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.
In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating bitches if the expected therapeutic benefits overweigh the potential risk.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. Do not exceed the recommended dosage.
In the case of overdose, symptomatic treatment should be initiated.
Dispose of used packaging in the household refuse. Unused product should be returned to the Veterinary Surgeon.
For animal treatment only.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Pharmaceutical precautions
Do not store above 25°C.
Store in the original package tightly closed in order to protect from moisture.
Keep out of reach and sight of children.
Legal category
POM-V
Packaging Quantities
50 tablets or 100 tablets of 1.25 mg tablets packed in white child-resistant polypropylene bottles.
50 tablets of 5.0 mg tablets packed in white child-resistant polypropylene bottles.
Further information
Pharmacodynamic properties
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity.
Pharmacokinetic particulars
Absorption:
Following oral administration of pimobendan, the absolute biovailability of the active principle is 60 - 63 %. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution:
The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93 %.
Metabolism:
The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.
Elimination:
The plasma elimination half-life of pimobendan is 0.4 + 0.1 hours, consistent with the high clearance of 90 + 19 ml/min/kg and a short mean residence time of 0.5 + 0.1 hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 + 0.3 hours. Almost the entire dose is eliminated via faeces.
Marketing authorisation number
Vm 00015/4077 Vetmedin 1.25 mg Flavour Tablets.
Vm 00015/4076 Vetmedin 5.0 mg Flavour Tablets.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
Vetmedin Flavour Tablets, containing 1.25 mg or 5.0 mg pimobendan per tablet.
Uses
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.
Dosage and administration
See dosing table below.
Vetmedin 1.25 mg and 5.0 mg Tablets Dosage Guide
| Bodyweight
| Daily Dosage
| Morning
| Evening
| (kg)
| (mg)
| 1.25 mg
| 5.0 mg
| 1.25 mg
| 5.0 mg
| < 5
| 1.25
| ½
| -
| ½
| -
| 5-10
| 2.5
| 1
| -
| 1
| -
| 11-20
| 5
| -
| ½
| -
| ½
| 21-40
| 10
| -
| 1
| -
| 1
| 41-60
| 20
| -
| 2
| -
| 2
| > 60
| 30
| -
| 3
| -
| 3
|
Vetmedin Flavour Tablets should be administered orally at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg bodyweight. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later. Each dose should be given approximately one hour before feeding. The tablet is flavoured and may be given as a treat. The large size of 5.0 mg can be readily divided into two halves, using the scored line on the tablet to give a dose that contains 2.5 mg. Do not exceed the recommended dosage.
Determine the bodyweight accurately before prescribing to ensure administration of the correct dosage.
Vetmedin Flavour Tablets may be combined with a diuretic treatment such as furosemide.
This product should be used only in dogs with cardiac insufficiency. Contra-indications, warnings, etc
Vetmedin Tablets should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.
In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating bitches if the expected therapeutic benefits overweigh the potential risk.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. Do not exceed the recommended dosage.
In the case of overdose, symptomatic treatment should be initiated.
Dispose of used packaging in the household refuse. Unused product should be returned to the Veterinary Surgeon.
For animal treatment only.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Pharmaceutical precautions
Do not store above 25°C.
Store in the original package tightly closed in order to protect from moisture.
Keep out of reach and sight of children.
Legal category
POM-V
Packaging Quantities
50 tablets or 100 tablets of 1.25 mg tablets packed in white child-resistant polypropylene bottles.
50 tablets of 5.0 mg tablets packed in white child-resistant polypropylene bottles.
Further information
Pharmacodynamic properties
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity.
Pharmacokinetic particulars
Absorption:
Following oral administration of pimobendan, the absolute biovailability of the active principle is 60 - 63 %. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution:
The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93 %.
Metabolism:
The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.
Elimination:
The plasma elimination half-life of pimobendan is 0.4 + 0.1 hours, consistent with the high clearance of 90 + 19 ml/min/kg and a short mean residence time of 0.5 + 0.1 hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 + 0.3 hours. Almost the entire dose is eliminated via faeces.
Marketing authorisation number
Vm 00015/4077 Vetmedin 1.25 mg Flavour Tablets.
Vm 00015/4076 Vetmedin 5.0 mg Flavour Tablets.
| 
